ESR1 and breast carcinoma: Moreover, the immunohistochemical study also demonstrated an association between BARHL1 downregulation and estrogen hormone negative breast cancers, which favors the BARHL-ESR1 link and might explain why estrogen replacement therapy improves the cognate condition of AD patients.